The European biotech sector is at a critical juncture. Despite producing world-class research with its share of the top 10% most-cited biomedical publications comparable to the US and China, European biotech companies attracted only 25 billion euros in venture capital from 2015 to mid-2025, compared to 219 billion euros in the United States (TechLifeSci, 2026). This disparity reveals the systemic challenges hindering commercialization within the sector. As companies struggle to bridge the gap between validated science and market entry, they risk stalling at key execution stages, ultimately compromising their ability to advance crucial healthcare solutions.

With the stakes this high, understanding the underlying bottlenecks in biotech execution is essential for companies, ecosystem partners, and investors alike. This article explores the pressing challenges at play and outlines how structured execution can pave the way for a more competitive European biotech landscape.

Why European Biotech Struggles to Commercialize

As we approach 2026, the European biotech sector finds itself navigating challenges that most companies cannot tackle alone. While the industry has demonstrated immense potential for innovation and economic growth, structural barriers at the execution level have hampered progress. The decline in the EU's share of commercially sponsored clinical trials, from 22% in 2013 to 12% in 2023, highlights a significant gap in Europe's ability to move research into clinical and commercial stages. Multinational trial decisions take on average 113 days compared to approximately 60 days in other regions, adding further pressure on companies racing against their patent clocks (European Commission, 2025).

In this context, companies face mounting pressure to not only secure funding but also to effectively deploy it against the right execution challenges at the right time. The need for a more agile and responsive approach has never been more apparent.

What Blocks Biotech Companies from Reaching the Market in Europe

To understand why European biotech companies stall before reaching the market, we must examine the specific execution bottlenecks that are distinct to this sector.

Fragmented regulatory pathways across the EU are the first barrier. The European Medicines Agency oversees centralized approvals, but individual member states maintain their own requirements for market access, pricing, reimbursement, and distribution. A biotech company commercializing across Europe is navigating multiple regulatory environments simultaneously, each with different timelines, documentation standards, and stakeholder expectations. This fragmentation is a primary driver of the clinical trials decline.

The IP exclusivity window creates the second pressure point. A biotech company's patent protection starts at filing, not at market entry. Every month spent navigating regulatory complexity, scaling manufacturing, or securing reimbursement is a month of commercial exclusivity lost. For companies with development timelines of 10 to 15 years, the remaining window for revenue generation can become critically short, making execution speed a direct determinant of commercial viability.

Manufacturing scale-up for biologics presents the third challenge. Unlike small-molecule drugs, biologics require specialized production processes including cell line development, process optimization, cold chain logistics, and batch consistency testing. Most early-stage biotech companies cannot build these capabilities in-house and must identify the right contract development and manufacturing partners while maintaining regulatory compliance across jurisdictions.

Reimbursement and market access strategy is the fourth bottleneck. Each European country runs its own health technology assessment process. Building evidence packages that satisfy local requirements, engaging payers at the right stage of development, and aligning clinical endpoints with reimbursement criteria requires expertise most biotech teams do not have internally.

These bottlenecks are interrelated. A delay in regulatory approval compresses the IP exclusivity window. Manufacturing challenges push back clinical timelines. Insufficient reimbursement strategy limits the markets where a product can generate revenue. The cumulative effect is that many European biotech companies run out of runway before they reach commercialization.

What the EU Biotech Act Does and Does Not Solve

The urgency for reform in the European biotech landscape is underscored by imminent policy shifts. The European Commission proposed the European Biotech Act in December 2025, aiming to streamline regulatory pathways and mobilize up to 10 billion euros in public-private biotech investment through the BioTechEU initiative with the European Investment Bank. The scale of the challenge is visible in a striking structural signal: 66 out of 67 EU-based biotech companies that went public over the past six years chose non-EU stock exchanges.

These policy reforms address structural barriers at the regulatory and funding level. But policy reform does not solve operational execution. A company that gains faster regulatory approval still needs the expertise to scale manufacturing, coordinate clinical trials across member states, and build a reimbursement strategy for each target market. The companies that will benefit most from the new policy environment are those that already have execution capabilities in place.

Why do European biotech companies fail before reaching the market?

The primary barriers are fragmented regulatory pathways across EU member states, IP exclusivity windows that shrink with every execution delay, biologics manufacturing complexity, and country-specific reimbursement requirements that most early-stage teams lack the expertise to navigate. These bottlenecks compound each other, and addressing them requires domain-specific fractional expertise at each stage rather than generalist support.

What is the EU Biotech Act and how does it affect biotech companies?

The EU Biotech Act, proposed in December 2025, aims to streamline clinical trial processes and mobilize up to 10 billion euros in public-private investment through BioTechEU. It addresses regulatory and funding barriers but does not solve operational execution challenges like manufacturing scale-up, multi-country market access, or reimbursement strategy.

Implementing Structured Execution to Overcome Challenges

Successfully navigating these bottlenecks requires a structured execution framework that brings in domain-specific expertise at each stage. Biotech companies that reach commercialization are those that strategically engage fractional experts matched to the specific challenge they face: regulatory specialists for pathway navigation, manufacturing experts for CDMO selection and scale-up, market access consultants for country-specific reimbursement strategies. This approach avoids building permanent teams for capabilities they only need at specific stages.

RESEARCHPRENEURS works with companies to close this gap. Through Pathfinder, we diagnose where a company is actually stuck, match them with the right vetted fractional expert, scope the project to clear milestones, and manage delivery. This structured approach allows biotech companies to move through each stage of commercialization with the right expertise at the right time.

The European biotech sector does not lack innovation. It lacks the execution infrastructure to turn that innovation into products patients can access. Structured execution is how that changes.

References

TechLifeSci. (2026). The €25B vs €219B Problem: Europe's Plan to Fix Biotech. European Commission. (2025). European Biotech Act proposal, COM/2025/1022.